| Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study | Lancet, The | 2021 | 118 |
| Local Control After Stereotactic Body Radiation Therapy for Liver Tumors | International Journal of Radiation Oncology Biology Physics | 2021 | 80 |
| IMMU-14. COMPUTATIONAL DECONVOLUTION OF TUMOR-INFILTRATING IMMUNE COMPONENTS IN PEDIATRIC NERVOUS SYSTEM TUMORS | Neuro-Oncology | 2021 | 78 |
| ECOA-8. Lung adenocarcinoma brain metastasis prediction using tumor DNA methylation profiling | Neuro-Oncology Advances | 2021 | 78 |
| Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy | Cell | 2021 | 68 |
| 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer | Thyroid | 2021 | 66 |
| Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction | Nature Genetics | 2021 | 62 |
| Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study | Journal of Clinical Oncology | 2021 | 62 |
| A proximity-dependent biotinylation map of a human cell | Nature | 2021 | 60 |
| Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | Journal of Clinical Oncology | 2021 | 59 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2021 | 58 |
| Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial | Journal of Clinical Oncology | 2021 | 57 |
| Quantitative single-cell proteomics as a tool to characterize cellular hierarchies | Nature Communications | 2021 | 53 |
| Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study | Lancet Oncology, The | 2021 | 53 |
| Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression | Nature Cell Biology | 2021 | 53 |
| RNA N-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the mA-GLUT1-mTORC1 Axis and Is a Therapeutic Target | Gastroenterology | 2021 | 48 |
| Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia | Journal of Clinical Oncology | 2021 | 45 |
| Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline | Journal of Clinical Oncology | 2021 | 42 |
| Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma | Journal of Clinical Oncology | 2021 | 39 |
| Beyond immune checkpoint blockade: emerging immunological strategies | Nature Reviews Drug Discovery | 2021 | 39 |
| Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study | Lancet Oncology, The | 2021 | 36 |
| Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group | Radiotherapy and Oncology | 2021 | 34 |
| Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies | Clinical Cancer Research | 2021 | 33 |
| A systematic review of rehabilitation and exercise recommendations in oncology guidelines | Ca-A Cancer Journal for Clinicians | 2021 | 32 |
| Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial | Lancet, The | 2021 | 32 |
